After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
The Q & A document from the Reentry Changes Webinar hosted on 06/06/18 has been posted in the Wh...
CTS will be transitioning to a new sFTP server for clients who send test request and/or receive...
We have now added a new section called the "Assay History List" to the "At A Gla...
CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...